← All Cumberland Pharmaceuticals INC filings

Cumberland Pharmaceuticals INC 10-K annual reports

Annual reports — audited financials, the full risk-factor list, and management’s account of the year.

NASDAQ
CPIX
Cumberland Pharmaceuticals INC
10-K: Cumberland Pharmaceuticals Reports Mixed Results in 2024 10-K Filing, Focuses on Pipeline Development
Cumberland Pharmaceuticals' 2024 10-K filing reveals a slight revenue decrease, strategic shifts in product focus, and continued investment in its clinical pipeline, particularly ifetroban.
NASDAQ
CPIX
Cumberland Pharmaceuticals INC
10-K: Cumberland Pharmaceuticals Details Stock Structure and Anti-Takeover Measures in 10-K Filing
Cumberland Pharmaceuticals' 10-K filing outlines its common stock characteristics, anti-takeover provisions, and business operations, including product portfolio and clinical pipeline.